Elevation Oncology, Inc. financial data

Symbol
ELEV on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
101 Federal Street, Suite 1900, Boston, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
14ner Oncology, Inc. (to 7/19/2019)
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.42K % +229%
Debt-to-equity 50.6 % -34.2%
Return On Equity -58 % +62.2%
Return On Assets -38.5 % +55.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 59.1M shares +39.5%
Common Stock, Shares, Outstanding 54.7M shares +29%
Entity Public Float 52.8M USD +137%
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 59M shares +108%
Weighted Average Number of Shares Outstanding, Diluted 54.6M shares +97.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 24.7M USD -60.3%
General and Administrative Expense 15M USD -8.27%
Operating Income (Loss) -39.7M USD +52.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -39.7M USD +53.3%
Income Tax Expense (Benefit) 42K USD +20%
Net Income (Loss) Attributable to Parent -39.7M USD +53.3%
Earnings Per Share, Basic -0.67 USD/shares +81.2%
Earnings Per Share, Diluted -0.67 USD/shares +81.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 59.4M USD -44.1%
Marketable Securities, Current 51.4M USD +3117%
Assets, Current 114M USD +3.79%
Property, Plant and Equipment, Net 45K USD -42.3%
Other Assets, Noncurrent 983K USD +13.4%
Assets 115M USD +3.83%
Accounts Payable, Current 344K USD -93.4%
Accrued Liabilities, Current 2.42M USD -23.8%
Liabilities, Current 2.76M USD -67.2%
Liabilities 33.7M USD -11.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -26K USD -1200%
Retained Earnings (Accumulated Deficit) -217M USD -22.4%
Stockholders' Equity Attributable to Parent 80.9M USD +12.1%
Liabilities and Equity 115M USD +3.83%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.58M USD +43.1%
Net Cash Provided by (Used in) Financing Activities 30.3M USD +13905%
Net Cash Provided by (Used in) Investing Activities 20.7M USD -22.2%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 54.7M shares +29%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 41.4M USD +314%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 59.4M USD -44.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 887K USD +66.7%
Deferred Tax Assets, Valuation Allowance 45.9M USD +30.4%
Deferred Tax Assets, Gross 45.9M USD +30.4%
Depreciation 10K USD 0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -39.7M USD +53.1%
Deferred Tax Assets, Operating Loss Carryforwards 20.2M USD +62.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 298M USD +19.4%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 3K USD -62.5%
Share-based Payment Arrangement, Expense 3.08M USD -22.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%